Scarica l'app Stockscreener
11.17
1.73%
0.19
Precedente Chiudi:
$10.98
Aprire:
$10.87
Volume 24 ore:
1.15M
Relative Volume:
0.59
Capitalizzazione di mercato:
$971.99M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-5.1475
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
-0.31%
1M Prestazione:
+16.60%
6M Prestazione:
+80.16%
1 anno Prestazione:
+11.03%
Intervallo 1D:
$10.86
$11.36
Intervallo di 1 settimana:
$10.50
$11.88
Portata 52W:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Confronta KURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
11.17 | 955.45M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Iniziato | Guggenheim | Neutral |
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Why The Narrative Around Kura Oncology Is Shifting After FDA Approval and Analyst Upgrades - Yahoo Finance
(KURA) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Will Kura Oncology Inc. stock benefit from infrastructure spendingQuarterly Growth Report & Stock Timing and Entry Methods - newser.com
How Kura Oncology Inc. stock performs in high volatility marketsEarnings Growth Summary & Long-Term Safe Investment Plans - newser.com
Kura Oncology at Jefferies Conference: Strategic Insights on Zypto By Investing.com - Investing.com Canada
Can Kura Oncology Inc. stock resist market sell offs2025 Macro Impact & Consistent Income Trade Ideas - newser.com
Is Kura Oncology Inc. showing signs of accumulationQuarterly Market Summary & High Return Stock Watch Alerts - newser.com
Is Kura Oncology Inc. stock recession proofJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com
How to monitor Kura Oncology Inc. with trend dashboards2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Candlestick signals on Kura Oncology Inc. stock todayJuly 2025 Sentiment & Detailed Earnings Play Strategies - newser.com
Can Kura Oncology Inc. stock resist sector downturnsRecession Risk & Daily Growth Stock Investment Tips - newser.com
FDA clears Kura/Kyowa’s Komzifti in r/r NPM1 mutant AML - BioWorld MedTech
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Komzifti™ (ziftomenib) - The Manila Times
Kura Oncology’s SWOT analysis: FDA approval boosts oncology stock amid pipeline expansion - Investing.com Canada
Kura Oncology (KURA) Price Target Increased by 14.48% to 31.53 - Nasdaq
Kura Oncology’s SWOT analysis: FDA approval boosts oncology stock amid pipeline expansion By Investing.com - Investing.com South Africa
Why Kura Oncology Inc. stock attracts high net worth investorsMarket Trend Report & Free Real-Time Volume Trigger Notifications - newser.com
Can Kura Oncology Inc. stock rebound after recent weaknessAnalyst Downgrade & Safe Entry Trade Signal Reports - newser.com
Kura Oncology wins FDA approval for leukemia drug - MSN
Is Kura Oncology Inc a good long term investmentTrading Psychology Tips & High Return Wealth Plans - earlytimes.in
Kura Oncology officer Powl sells $99,329 in shares By Investing.com - Investing.com Nigeria
Kura oncology chief medical officer Leoni sells $173k in stock By Investing.com - Investing.com South Africa
Signal strength of Kura Oncology Inc. stock in tech scannersPortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
Kura oncology chief medical officer Leoni sells $173k in stock - Investing.com Canada
Kura Oncology chief legal officer Bair sells $98k in stock - Investing.com Canada
Kura Oncology officer Powl sells $99,329 in shares - Investing.com India
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):